α‐Synuclein RT‐QuIC assay in cerebrospinal fluid of patients with dementia with Lewy bodies

• Published in: Annals of clinical and translational neurology Vol. 6; no. 10; pp. 2120 - 2126
• Main Authors: Bongianni, Matilde, Ladogana, Anna, Capaldi, Stefano, Klotz, Sigrid, Baiardi, Simone, Cagnin, Annachiara, Perra, Daniela, Fiorini, Michele, Poleggi, Anna, Legname, Giuseppe, Cattaruzza, Tatiana, Janes, Francesco, Tabaton, Massimo, Ghetti, Bernardino, Monaco, Salvatore, Kovacs, Gabor G., Parchi, Piero, Pocchiari, Maurizio, Zanusso, Gianluigi
• Format: Journal Article
• Language: English
• Published: United States John Wiley & Sons, Inc 01.10.2019; John Wiley and Sons Inc; Wiley
• Subjects: Brief Communication; Brief Communications; Dementia; Encephalitis; Laboratories; Neuropathology; Parkinson's disease; Pathology; Proteins
• ISSN: 2328-9503; 2328-9503
• DOI: 10.1002/acn3.50897

We applied RT‐QuIC assay to detect α‐synuclein aggregates in cerebrospinal fluid (CSF) of patients with suspected Creutzfeldt–Jakob disease who had a neuropathological diagnosis of dementia with Lewy bodies (DLB) (n = 7), other neurodegenerative diseases with α‐synuclein mixed pathology (n = 20), or without Lewy‐related pathology (n = 49). The test had a sensitivity of 92.9% and specificity of 95.9% in distinguishing α‐synucleinopathies from non‐α‐synucleinopathies. When performed in the CSF of patients with DLB (n = 36), RT‐QuIC was positive in 17/20 with probable DLB, 0/6 with possible DLB, and 0/10 with Alzheimer disease. These results indicate that RT‐QuIC for α‐synuclein is an accurate test for DLB diagnosis.